Have a personal or library account? Click to login
Down-regulation of miRNA-30c predicts poor prognosis in Colorectal Cancer patients Cover

Down-regulation of miRNA-30c predicts poor prognosis in Colorectal Cancer patients

Open Access
|Dec 2016

Abstract

Background: MiRNA-30c was a tumor suppressor in several human cancers, however, its association with clinicopathological features and prognosis in colorectal cancer (CRC) is unclear.

Materials and Methods: The expression level of miRNA-30c in 192 pairs of colorectal cancer and adjacent normal tissues was detected by Quantitative RT-PCR, the association between miRNA-30c expression and clinical characteristics and prognosis were statistically analyzed.

Results: miRNA-30c was significantly lower in CRC tissues specimens compared with matched normal adjacent tissue (P<0.001). MiRNA-30c was positively correlated with tumor size (P=0.012), TMN stage (P=0.002) and lymph node metastasis (P=0.004). The univariate analysis showed CRC patients with low miRNA-30c had distinctly shorter overall survival (P<0.001) than patients with high miRNA-30c expression level. The multivariate analysis was performed and informed that low miRNA-30c expression (P<0.001) might be an independent prognostic predictor for poor prognosis.

Conclusion: miRNA-30c could predict the prognosis of colorectal cancer which is helpful to choose reasonable treatment measures.

DOI: https://doi.org/10.1515/rrlm-2016-0037 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 369 - 375
Submitted on: Jun 7, 2016
Accepted on: Oct 6, 2016
Published on: Dec 30, 2016
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2016 Liu Bin, Meng Zhang, Liu Lixia, Zang Aimin, Yang Hua, Shang Yanhong, Yang Yang, Gao Feng, Liu Bo, Zhang Yonggang, Tian Huiping, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.